All In Biotech

Free tool

FAERS Monitor: Kepivance

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125103 or its brand name (Kepivance, Palifermin). Reports on generic versions are filed under their own applications.

Reports

389

Serious

351

90% of reports

Hospitalization

154

Death reported

67

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • mucosal inflammation56
  • febrile neutropenia39
  • rash39
  • stomatitis34
  • erythema28
  • sepsis24
  • pyrexia23
  • diarrhoea20
  • neutropenia20
  • infection19
  • oedema peripheral19
  • off label use19
  • pruritus19
  • pain17
  • skin exfoliation17

Reports by year received

View as table
YearReports
200523
200660
200760
200855
200917
20102
20119
20124
20137
20144
201519
201619
201747
201816
20198
202011
20216
20224
20237
20245
20252
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,770 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mucosal inflammationSignal56115.990.96,259
febrile neutropeniaSignal3931.823.61,136
stomatitisSignal3430.322.0937
sepsisSignal2411.67.9224
skin exfoliationSignal1710.96.8144
oedema peripheralSignal198.45.4118
neutropeniaSignal208.05.2115
erythemaSignal287.45.2149
infectionSignal197.14.694
rashSignal394.83.6117
pyrexiaSignal233.62.441
pruritusSignal192.71.719
diarrhoea201.71.15
pain171.50.92
off label use191.20.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.